Orchestra BioMed Holdings, Inc. (OBIO): Nasdaq/NYSE listing notice — Health Sciences Acquisitions Corp 2 receives Nasdaq delisting notice for failing to hold annual meeting

Orchestra BioMed Holdings, Inc.

Received Nasdaq notice on Jan 19, 2023 for failure to hold annual meeting within 12 months after FY2021 end (Dec 31, 2021).
Has until March 5, 2023 to submit compliance plan; if accepted, deadline extended to June 29, 2023.
Company does not intend to submit plan; expects to resolve via business combination with Orchestra BioMed at Jan 24, 2023 meeting.
If business combination approved, combined company treated as newly listed; annual meeting due by Dec 31, 2024.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Orchestra BioMed Holdings, Inc. received a nasdaq deficiency notice notice regarding other (rules 5620(a)).

Exchange: nasdaq
Notice: deficiency notice
Rules: 5620(a)

Exact text from the filing

a Cayman Islands exempted company (“ HSAC2 ” or the “ Company ”), received a notice from The Nasdaq Stock Market (“ Nasdaq ”) stating that the Company failed to hold an annual meeting of stockholders within 12 months after its fiscal year ended December 31, 2021, as required by Nasdaq Listing Rule 5620(a). In accordance with Nasdaq Listing Rule 5810(c)(2)(G), the Company has 45 calendar days (or until March 5, 2023) to submit a plan to regain compliance and, if Nasdaq accepts the plan, Nasdaq may grant the Company up to 180 calendar days from its fiscal year end, or until June 29, 2023, to re

View on SEC.gov

50 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Orchestra BioMed Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-23-004618

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.